ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
62.37
-0.14 (-0.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close62.51
Open62.49
Bid59.00 x 1000
Ask0.00 x 3200
Day's Range62.06 - 62.58
52 Week Range44.21 - 64.60
Volume3,839,066
Avg. Volume6,241,060
Market Cap109.346B
Beta1.67
PE Ratio (TTM)231.86
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.12 (1.88%)
Ex-Dividend Date2018-04-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • How to Invest in Diabetes Stocks
    Motley Foolyesterday

    How to Invest in Diabetes Stocks

    Here's everything you need to know about investing in the fast-growing diabetes market.

  • Top Stock Reports for Duke Energy, Charter Communications & Abbott
    Zacks2 days ago

    Top Stock Reports for Duke Energy, Charter Communications & Abbott

    Top Stock Reports for Duke Energy, Charter Communications & Abbott

  • Motley Fool2 days ago

    Five Top MedTech Stocks in Diabetes

    Medical devices companies are revolutionizing how patients control their diabetes.

  • InvestorPlace2 days ago

    A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future

    While steady growth is appreciated by some investors, that’s not that great overall and doesn’t necessarily support its constant valuation premium. To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. Vision care is quickly becoming a major growth engine for JNJ.

  • Abbott Presents Positive Study Results for Tendyne Device
    Zacks2 days ago

    Abbott Presents Positive Study Results for Tendyne Device

    Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

  • Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
    Zacks3 days ago

    Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

    Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

  • The Performance of Roche’s Diagnostics Division in Q1 2018
    Market Realist6 days ago

    The Performance of Roche’s Diagnostics Division in Q1 2018

    Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.

  • Shocking the Spine Offers an Alternative to Opioids
    Bloomberg6 days ago

    Shocking the Spine Offers an Alternative to Opioids

    Like millions of people caught up in America’s opioid crisis, Rick Surkin used to take a pill just to get out of bed in the morning. Until last year, the former firefighter relied on thrice-daily doses of the powerful painkiller OxyContin to numb the agony from a ruptured disc in his back. The series of tiny shocks, known as neuromodulation, has kept Surkin comfortable enough to ditch Oxy.

  • Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
    Zacks9 days ago

    Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

    Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • How Did Bausch + Lomb Perform in 1Q18?
    Market Realist12 days ago

    How Did Bausch + Lomb Perform in 1Q18?

    In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.

  • Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?
    Simply Wall St.12 days ago

    Will Abbott Laboratories (NYSE:ABT) Continue To Underperform Its Industry?

    Abbott Laboratories (NYSE:ABT) generated a below-average return on equity of 1.19% in the past 12 months, while its industry returned 10.98%. ABT’s results could indicate a relatively inefficient operation toRead More...

  • The Wall Street Journal15 days ago

    [$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

    An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist18 days ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • How Analysts View Allergan after Its 1Q18 Earnings
    Market Realist19 days ago

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist19 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • Is It Time To Buy Abbott Laboratories (NYSE:ABT)?
    Simply Wall St.19 days ago

    Is It Time To Buy Abbott Laboratories (NYSE:ABT)?

    Today we’re going to take a look at the well-established Abbott Laboratories (NYSE:ABT). The company’s stock received a lot of attention from a substantial price movement on the NYSE overRead More...

  • A Brief Look at Abbott’s Alere Integration Progress and Recovery
    Market Realist20 days ago

    A Brief Look at Abbott’s Alere Integration Progress and Recovery

    (Continued from Prior Part)Alere acquisition integration progress Abbott Laboratories (ABT) completed its acquisition of Alere in October 2017. The company has experienced significant difficulties with the acquisition over the past year. Let’s take a look at how the acquisition has progressed. According to Abbott Laboratories, the bulk of the integration work is complete, and the company has established strategies and plans for the Alere business.  The company added that the Alere acquisition’s synergies are on track, and the company seems to have benefited from the deal. ...

  • Discussing Abbott’s Market Position and Growth Prospects in China
    Market Realist20 days ago

    Discussing Abbott’s Market Position and Growth Prospects in China

    Abbott Laboratories (ABT) has registered some pressure in its China Nutritionals business. Over the past year, the market has seen trends such as oversupply leading to price discounting due to new food safety regulations that should become effective in 2018. Since the new food safety regulations have come into effect starting January 1, China’s nutrition market has seen improving market conditions.

  • Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
    Market Realist20 days ago

    Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?

    In 1Q18, Abbott Laboratories (ABT) reported sales of $535.0 million in its CRM (Cardiac Rhythm Management) business, which contributed ~19.5% to the company’s total sales of $2.7 billion in the quarter. The segment’s sales, however, registered flat YoY (year-over-year) growth on an organic basis. Abbott’s Cardiovascular segment—consisting of its Rhythm Management, Electrophysiology, Heart Failure, Structural Heart, and Vascular businesses—reported sales of $2.1 billion in 1Q18.

  • Forbes22 days ago

    Despite Youth On Farm, Abbott Ventures Chief Avoids Spreading Manure

    Abbott Ventures chief Evan Norton may have spent part of his youth on a farm, but there’s no manure in his manner when speaking of the medical device and diagnostics market landscape. The key, he says, is to avoid being blindsided by the transformational power of digital data. “We’ve been competing against Medtronic and J&J, so that has the risk of us being disintermediated by other players that come into the market,” Norton told attendees at MedCity Invest, a meeting focused on health care entrepreneurs.

  • Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
    Market Realist23 days ago

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.